{"id":335613,"date":"2019-09-26T02:00:00","date_gmt":"2019-09-26T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/blocage-des-recepteurs-de-peptides-efficace-et-sur-meme-a-long-terme\/"},"modified":"2019-09-26T02:00:00","modified_gmt":"2019-09-26T00:00:00","slug":"blocage-des-recepteurs-de-peptides-efficace-et-sur-meme-a-long-terme","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/blocage-des-recepteurs-de-peptides-efficace-et-sur-meme-a-long-terme\/","title":{"rendered":"Blocage des r\u00e9cepteurs de peptides efficace et s\u00fbr, m\u00eame \u00e0 long terme"},"content":{"rendered":"<p><strong>On estime qu&#8217;environ 11% de la population souffre de migraines. Des options th\u00e9rapeutiques efficaces, notamment pour la prophylaxie, sont donc n\u00e9cessaires de toute urgence. Les r\u00e9sultats des \u00e9tudes confirment d\u00e9sormais l&#8217;efficacit\u00e9 \u00e0 long terme de l&#8217;erenumab.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>L&#8217;anticorps anti-r\u00e9cepteur CGRP pour la pr\u00e9vention de la migraine Erenumab (<sup>Aimovig\u00ae<\/sup>) 140&nbsp;mg r\u00e9duit \u00e0 la fois le nombre de jours de migraine par mois (MMD) et le nombre de jours d&#8217;utilisation mensuelle de m\u00e9dicaments symptomatiques sp\u00e9cifiques de la migraine (MSMD), selon les \u00e9valuations des donn\u00e9es de l&#8217;\u00e9tude. Les patients ont montr\u00e9 une am\u00e9lioration rapide de tous les param\u00e8tres d&#8217;efficacit\u00e9 aux semaines 13-16 et 21-24. Les r\u00e9sultats li\u00e9s \u00e0 l&#8217;incapacit\u00e9 physique des patients et \u00e0 leur capacit\u00e9 \u00e0 participer aux activit\u00e9s quotidiennes ont \u00e9galement montr\u00e9 une am\u00e9lioration. Cette efficacit\u00e9 \u00e0 long terme est particuli\u00e8rement importante pour les patients qui n&#8217;ont pas encore pu b\u00e9n\u00e9ficier d&#8217;un traitement pr\u00e9ventif efficace.<\/p>\n<h2 id=\"reduction-significative-de-la-medication-aigue\">R\u00e9duction significative de la m\u00e9dication aigu\u00eb<\/h2>\n<p>Le fait que le nombre de jours de traitement de la migraine aigu\u00eb peut \u00eatre r\u00e9duit de moiti\u00e9 est \u00e9galement soulign\u00e9 par les donn\u00e9es de la phase de traitement actif de STRIVE. Ici, l&#8217;efficacit\u00e9 et la s\u00e9curit\u00e9 de l&#8217;\u00e9r\u00e9numab 70 et 140&nbsp;mg ont \u00e9t\u00e9 \u00e9valu\u00e9es chez des patients souffrant de migraines \u00e9pisodiques avec des \u00e9checs ant\u00e9rieurs de traitement pr\u00e9ventif. 55% des patients ayant re\u00e7u 140&nbsp;mg d&#8217;anticorps anti-r\u00e9cepteur CGRP ont pr\u00e9sent\u00e9 une r\u00e9duction d&#8217;au moins 50% du nombre de jours de migraine mensuels n\u00e9cessitant une m\u00e9dication aigu\u00eb. L&#8217;efficacit\u00e9 a \u00e9t\u00e9 d\u00e9montr\u00e9e de mani\u00e8re durable jusqu&#8217;\u00e0 la 52e semaine.<br \/>\n&nbsp;<\/p>\n<p><em>Sources :<\/em><\/p>\n<ul>\n<li><em>Media-Update &#8220;Novartis data underpin long-term efficacy of <sup>Aimovig\u00ae<\/sup> where other treatments have failed&#8221;, 01.07.2019.<\/em><\/li>\n<li><em>Media-Update &#8220;Novartis data show <sup>Aimovig\u00ae<\/sup> cuts acute migraine medication days by half in patients who failed prior preventive therapies&#8221;, 01.07.2019.<\/em><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><em>PRATIQUE DU M\u00c9DECIN DE FAMILLE 2019 ; 14(8) : 48<br \/>\nInFo NEUROLOGIE &amp; PSYCHIATRIE 2019 ; 17(5) : 36<\/em><br \/>\n&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On estime qu&#8217;environ 11% de la population souffre de migraines. Des options th\u00e9rapeutiques efficaces, notamment pour la prophylaxie, sont donc n\u00e9cessaires de toute urgence. Les r\u00e9sultats des \u00e9tudes confirment d\u00e9sormais&hellip;<\/p>\n","protected":false},"author":7,"featured_media":91042,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Pr\u00e9vention de la migraine","footnotes":""},"category":[11527,11545,11315,11383,11549],"tags":[13866,13867],"powerkit_post_featured":[],"class_list":["post-335613","post","type-post","status-publish","format-standard","has-post-thumbnail","category-etudes","category-marche-medecine","category-medecine-interne-generale","category-neurologie-fr","category-rx-fr","tag-maux-de-tete","tag-migraine-fr","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-02 21:05:55","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":335615,"slug":"il-blocco-dei-recettori-peptidici-e-efficace-e-sicuro-anche-a-lungo-termine","post_title":"Il blocco dei recettori peptidici \u00e8 efficace e sicuro anche a lungo termine.","href":"https:\/\/medizinonline.com\/it\/il-blocco-dei-recettori-peptidici-e-efficace-e-sicuro-anche-a-lungo-termine\/"},"pt_PT":{"locale":"pt_PT","id":335626,"slug":"bloqueio-do-receptor-do-peptideo-tambem-eficaz-e-seguro-a-longo-prazo","post_title":"Bloqueio do receptor do pept\u00eddeo tamb\u00e9m eficaz e seguro a longo prazo","href":"https:\/\/medizinonline.com\/pt-pt\/bloqueio-do-receptor-do-peptideo-tambem-eficaz-e-seguro-a-longo-prazo\/"},"es_ES":{"locale":"es_ES","id":335617,"slug":"el-bloqueo-de-los-receptores-peptidicos-tambien-es-eficaz-y-seguro-a-largo-plazo","post_title":"El bloqueo de los receptores pept\u00eddicos tambi\u00e9n es eficaz y seguro a largo plazo","href":"https:\/\/medizinonline.com\/es\/el-bloqueo-de-los-receptores-peptidicos-tambien-es-eficaz-y-seguro-a-largo-plazo\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/335613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=335613"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/335613\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/91042"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=335613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=335613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=335613"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=335613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}